Table 2.

Anti-tumor effects of trifluridine/tipiracil (FTD/TPI) and regorafenib in mice implanted with COLO205 human colorectal tumors.

Group	Dose (mg/kg/day)	Treatment	n	RTV(mean ± SD)	TGI(%)
Control	-	-	6	22.83 ± 2.07	-
FTD/TPI	150	Day 1–14 (b.i.d.)	6	7.02 ± 1.02 a	69.3
Regorafenib	10	Day 1–14 (q.d.)	6	7.09 ± 1.05 a	68.9
FTD/TPI followed by Regorafenib	150 + 10	-	6	1.76 ± 0.29 a,b	92.3

RTV: Relative tumor volume on day 29; TGI: Tumor growth-inhibition ratio on day 29; b.i.d.: bis in die; q.d.: quaque die; ^a p < 0.01 with a two-sided Aspin-Welch t-test, compared to control; ^b p < 0.01 with a two-sided Aspin-Welch t-test, compared to either monotherapy.